Price T Rowe Associates Inc. MD Boosts Holdings in Pharvaris (NASDAQ:PHVS)

Price T Rowe Associates Inc. MD increased its position in shares of Pharvaris (NASDAQ:PHVS - Free Report) by 36.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 443,896 shares of the company's stock after acquiring an additional 118,408 shares during the period. Price T Rowe Associates Inc. MD owned about 0.85% of Pharvaris worth $8,510,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently added to or reduced their stakes in the business. Legal & General Group Plc raised its stake in Pharvaris by 11.2% during the fourth quarter. Legal & General Group Plc now owns 9,855 shares of the company's stock worth $189,000 after acquiring an additional 994 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Pharvaris by 3.7% during the 4th quarter. Geode Capital Management LLC now owns 38,333 shares of the company's stock valued at $735,000 after purchasing an additional 1,356 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Pharvaris by 1,125.3% during the fourth quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock worth $59,000 after buying an additional 2,847 shares in the last quarter. Barclays PLC bought a new stake in shares of Pharvaris during the 3rd quarter worth approximately $106,000. Finally, KLP Kapitalforvaltning AS bought a new position in Pharvaris during the fourth quarter worth about $111,000.

Analyst Ratings Changes

Several analysts recently weighed in on PHVS shares. Cantor Fitzgerald started coverage on Pharvaris in a research note on Tuesday, April 29th. They issued an "overweight" rating and a $28.00 price objective on the stock. JMP Securities upped their price objective on shares of Pharvaris from $46.00 to $55.00 and gave the company a "market outperform" rating in a report on Friday, January 31st.

Pharvaris Stock Performance

Shares of NASDAQ PHVS traded down $0.08 during midday trading on Friday, hitting $16.96. 6,398 shares of the company traded hands, compared to its average volume of 58,909. The firm has a market cap of $886.84 million, a P/E ratio of -6.06 and a beta of -2.85. The stock has a 50-day moving average price of $15.24 and a 200 day moving average price of $17.93. Pharvaris has a 12-month low of $11.51 and a 12-month high of $25.50.

Pharvaris (NASDAQ:PHVS - Get Free Report) last released its quarterly earnings data on Monday, April 7th. The company reported ($0.68) earnings per share for the quarter, topping analysts' consensus estimates of ($0.74) by $0.06. As a group, equities analysts expect that Pharvaris will post -2.71 earnings per share for the current year.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.